Concord Biotech Q3 Results
- BSE: 543960
- NSE: CONCORDBIO
- ISIN: INE338H01029
- Sector: Biotechnology & Drugs
BSE
1,183.25
-45.75 (-3.72%)
-45.75 (-3.72%)Volume6.76 K
Updated: Fri 13 Feb, 2026 | 15:47:49
NSE
1,184.40-44.50 (-3.62%)
-44.50 (-3.62%)Volume1.09 L
Updated: Fri 13 Feb, 2026 | 15:40:25
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Income₹277.77 Cr.(13.74%)
- Operating Profit₹76.96 Cr.(-9.13%)
- Profit After Tax₹64.48 Cr.(-15.07%)
- Operating Margin27.71%(-20.10%)
Note: Comparison is on YoY basis
Quarterly - Concord Biotech Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 200.81 | 186.82 | 13.48% | 148.40 | 25.87% |
| Depreciation/ Amortization | 18.75 | 13.31 | 1.93% | 13.54 | 41.34% |
| Operating Income | 76.96 | 123.36 | 9.78% | 92.39 | -9.13% |
| Net Income | 64.48 | 95.74 | 2.24% | 77.57 | -15.07% |
| Other Operating Expenses Total | 37.83 | 63.52 | 3.46% | 57.11 | -36.12% |
| Net Income Before Taxes | 86.16 | 130.34 | 0.55% | 103.10 | -14.83% |
| Total Revenue | 277.77 | 310.18 | 12.43% | 240.80 | 13.74% |
| Selling/ General/ Admin Expenses Total | 46.78 | 33.66 | 5.23% | 30.67 | 35.05% |
| Diluted Normalized EPS | 6.31 | 14.85 | 4.96% | 7.41 | -13.11% |